ClfA Antibody Targeting Fibrinogen Binding in S. aureus

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Staphylococcus aureus infections pose significant health concerns due to antibiotic resistance, and current vaccination attempts have been unsuccessful due to the pathogen's ability to dampen the immune response through elaborate evasion molecules, making it difficult to develop effective therapeutic strategies.

Innovation Solution

A pharmaceutical composition comprising monoclonal or polyclonal antibodies or antigen-binding fragments that specifically bind to ClfA, reducing fibrinogen binding to gram-positive bacteria, potentially combined with antibiotics, to inhibit bacterial virulence and infection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If vaccination attempts are made against S. aureus, then immune response is stimulated, but the pathogen's evasion molecules dampen the immune response and prevent effective vaccine development

Engineering Contradiction:

Improvevaccine effectivenessVSAvoidimmune evasion by pathogen

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and targets specific virulence factors (ClfA and its fibrinogen binding site) rather than attempting to stimulate general immune response against the entire pathogen. By isolating and neutralizing the specific evasion molecule ClfA that dampens immune response, the invention bypasses the pathogen's immune evasion mechanisms while still providing protective immunity.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses monoclonal antibodies as intermediaries that specifically bind to ClfA and block its fibrinogen binding site. These antibodies act as mediators between the immune system and the pathogen, neutralizing the harmful ClfA molecule without triggering the pathogen's evasion response, thereby enabling effective immunotherapy despite the pathogen's immune suppression capabilities.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If antibiotics are used to treat S. aureus infections, then bacterial growth is inhibited, but antibiotic resistance develops rendering treatment ineffective

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidantibiotic resistance

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harm caused by antibiotic resistance into a benefit by targeting a completely different mechanism of action. Instead of inhibiting bacterial growth through antibiotics to which resistance has developed, the invention uses monoclonal antibodies that neutralize virulence factors, thereby converting the resistance problem into an opportunity for alternative therapeutic approaches that bypass resistant pathways.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the therapeutic parameter from antibacterial growth inhibition (antibiotics) to virulence factor neutralization (monoclonal antibodies). This parameter change allows treatment of S. aureus infections even when antibiotic resistance is present, as the monoclonal antibodies target ClfA's fibrinogen binding function rather than bacterial cell wall or protein synthesis pathways.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If monoclonal antibodies targeting ClfA are administered, then fibrinogen binding to bacteria is reduced, but the complexity of identifying and targeting the correct epitope increases

Engineering Contradiction:

Improveinhibition of fibrinogen bindingVSAvoidepitope identification and targeting

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies local quality by targeting a specific local region (the fibrinogen binding site on ClfA) rather than attempting to bind to the entire ClfA molecule or multiple regions. The monoclonal antibodies are designed to specifically recognize and bind to the epitope sequence corresponding to the fibrinogen binding site, concentrating the inhibitory effect precisely where it is needed to block fibrinogen binding and reduce bacterial virulence.

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively inhibits the binding of fibrinogen to ClfA, thereby reducing bacterial virulence and the severity of infections, providing a novel approach to treat and prevent Staphylococcus aureus infections, including sepsis and thromboembolic lesions.

Implementation Method 1

a heavy chain, a light chain with a variable region that bind at least a portion of a N3 fibrinogen binding site of the ClfA

Methodology Applied

Scientific EffectAntigen-antibody binding:

Data Source

PatentUS11446371B2Targeting of ligand binding sites in ClfA

Publication Date: 2022.09.20 TEXAS A&M UNIVERSITY

AI summary

The present invention provides methods and compositions to reduce binding of fibrinogen to the ClfA in a gram positive bacterial infections using monoclonal antibody, a polyclonal antibody, an antigen-binding antibody fragment or a composition that specifically binds to a portion of ClfA with the sequence of SEQ ID No: 15, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.